According to GlobalData’s medical device pipeline database, nine 1-injection devices are in various stages of development globally. GlobalData’s report 1-injection provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, seven are in active development, while the remaining three are in an inactive stage of development. There are one products in the early stages of development, and the remaining six are in the late stages of development.
Hyaluronic acid is given as a one-dose injection. One unit refers to one injection of Hyaluronic acid.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed 1-injection pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of 1-injection devices. Overall, most of these 1-injection pipeline devices are being developed by private entities.
Key players involved in the active development of 1-injection include Anika Therapeutics, Ampio Pharmaceuticals, Labrha International, LG Chem and Shin Poong Pharm.
For a complete picture of the developmental pipeline for 1-injection devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.